Aripiprazole oral soluble film - CMG Pharmaceutical

Drug Profile

Aripiprazole oral soluble film - CMG Pharmaceutical

Alternative Names: Aripiprazole - CMG Pharmaceutical

Latest Information Update: 07 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CMG Pharmaceutical
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor agonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 01 Mar 2016 CMG Pharmaceutical completes a phase I trial in Schizophrenia in Canada, USA (PO) (NCT02501109)
  • 01 Oct 2015 Phase-I clinical trials in Schizophrenia in Canada, USA (PO) (NCT02501109)
  • 04 Jun 2015 CMG Pharmaceutical plans a phase I trial for Schizophrenia in USA and Canada (NCT02501109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top